
|Videos|November 5, 2021
Nonsteroidal Mineralcorticoid Receptor Antagonists in Managing Hyperkalemia
Dr. Cary Boyd-Shiwarski explains how nonsteroidal mineralcorticoid receptor antagonists and novel potassium-binding agents alter the management of hyperkalemia and approaching potassium handling in chronic kidney disease.
Advertisement
Pharmacy Times spoke to Dr. Cary Boyd-Shiwarski about her session at the ASN 2021 conference titled "Mechanisms of Potassium Handling in CKD."
Boyd explained how nonsteroidal mineralcorticoid receptor antagonists and novel potassium-binding agents alter the management of hyperkalemia and approaching potassium handling in chronic kidney disease.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Polycystic Ovary Syndrome Undergoes Name Change: Polyendocrine Metabolic Ovarian Syndrome
2
Amid Mounting Pressure, FDA Commissioner Marty Makary Resigns
3
GLP-1 Receptor Agonists Linked to Improved Survival Outcomes in Breast Cancer
4
From Misdiagnosis to Advocacy: Addressing Bias and Equity in Heart Failure Management
5


































































































































